Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories
Background Detection of the pathological and disease-associated alpha-synuclein (αSyn D ) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSyn D can be detected in the olfactory mucosa (OM) of MSA a...
Saved in:
Published in | Molecular neurodegeneration Vol. 16; no. 1; pp. 82 - 19 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
11.12.2021
BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1750-1326 1750-1326 |
DOI | 10.1186/s13024-021-00491-y |
Cover
Abstract | Background
Detection of the pathological and disease-associated alpha-synuclein (αSyn
D
) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSyn
D
can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes.
Methods
OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (
n
= 20, mean disease duration 4.4 years), MSA-C (
n
= 10, mean disease duration 4 years), PD (
n
= 13, mean disease duration 8 years), and healthy control subjects (HS) (
n
= 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data.
Results
The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83–1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability.
Conclusions
Our study provides evidence that OM-αSyn
D
may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials. |
---|---|
AbstractList | Background Detection of the pathological and disease-associated alpha-synuclein ([alpha]Syn.sup.D) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that [alpha]Syn.sup.D can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on [alpha]-synuclein Real-Time Quaking-Induced Conversion ([alpha]Syn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. Methods OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by [alpha]Syn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized [alpha]Syn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. Results The [alpha]Syn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, [alpha]Syn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce [alpha]Syn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the [alpha]Syn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Conclusions Our study provides evidence that OM-[alpha]Syn.sup.D may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, [alpha]Syn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials. Keywords: Alpha-synuclein, Olfactory mucosa, Real-Time Quaking-Induced Conversion, Misfolding, Biomarkers Detection of the pathological and disease-associated alpha-synuclein ([alpha]Syn.sup.D) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that [alpha]Syn.sup.D can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on [alpha]-synuclein Real-Time Quaking-Induced Conversion ([alpha]Syn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by [alpha]Syn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized [alpha]Syn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. The [alpha]Syn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, [alpha]Syn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce [alpha]Syn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the [alpha]Syn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Our study provides evidence that OM-[alpha]Syn.sup.D may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, [alpha]Syn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials. Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that αSynD can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes.BACKGROUNDDetection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that αSynD can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes.OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data.METHODSOM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data.The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability.RESULTSThe αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability.Our study provides evidence that OM-αSynD may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.CONCLUSIONSOur study provides evidence that OM-αSynD may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials. Background Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSynD can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. Methods OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. Results The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83–1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Conclusions Our study provides evidence that OM-αSynD may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials. Detection of the pathological and disease-associated alpha-synuclein (αSyn ) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that αSyn can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Our study provides evidence that OM-αSyn may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials. Background Detection of the pathological and disease-associated alpha-synuclein (αSyn D ) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSyn D can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. Methods OM samples were prospectively collected from patients with a probable diagnosis of MSA-P ( n = 20, mean disease duration 4.4 years), MSA-C ( n = 10, mean disease duration 4 years), PD ( n = 13, mean disease duration 8 years), and healthy control subjects (HS) ( n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. Results The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83–1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Conclusions Our study provides evidence that OM-αSyn D may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials. Abstract Background Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSynD can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. Methods OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. Results The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83–1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Conclusions Our study provides evidence that OM-αSynD may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials. |
ArticleNumber | 82 |
Audience | Academic |
Author | Di Fonzo, Alessio Legname, Giuseppe Cazzaniga, Federico Angelo Tramacere, Irene Bistaffa, Edoardo Giaccone, Giorgio Wang, Wen Felisati, Giovanni Chen, Shu Guang Portaleone, Sara Maria Gunzler, Steven Alexander De Luca, Chiara Maria Giulia Bargar, Connor Devigili, Grazia Eleopra, Roberto Elia, Antonio Emanuele Xu, Rong Cilia, Roberto Moda, Fabio |
Author_xml | – sequence: 1 givenname: Connor surname: Bargar fullname: Bargar, Connor organization: Department of Pathology, Case Western Reserve University School of Medicine – sequence: 2 givenname: Chiara Maria Giulia surname: De Luca fullname: De Luca, Chiara Maria Giulia organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA) – sequence: 3 givenname: Grazia surname: Devigili fullname: Devigili, Grazia organization: Unit of Neurology 1 - Parkinson and Movement Disorders, Fondazione IRCCS Istituto Neurologico Carlo Besta – sequence: 4 givenname: Antonio Emanuele surname: Elia fullname: Elia, Antonio Emanuele organization: Unit of Neurology 1 - Parkinson and Movement Disorders, Fondazione IRCCS Istituto Neurologico Carlo Besta – sequence: 5 givenname: Roberto surname: Cilia fullname: Cilia, Roberto organization: Unit of Neurology 1 - Parkinson and Movement Disorders, Fondazione IRCCS Istituto Neurologico Carlo Besta – sequence: 6 givenname: Sara Maria surname: Portaleone fullname: Portaleone, Sara Maria organization: Department of Health Science, Santi Paolo e Carlo Hospital and Università degli Studi di Milano – sequence: 7 givenname: Wen surname: Wang fullname: Wang, Wen organization: Department of Pathology, Case Western Reserve University School of Medicine – sequence: 8 givenname: Irene surname: Tramacere fullname: Tramacere, Irene organization: Scientific Directorate, Fondazione IRCCS Istituto Neurologico Carlo Besta – sequence: 9 givenname: Edoardo surname: Bistaffa fullname: Bistaffa, Edoardo organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta – sequence: 10 givenname: Federico Angelo surname: Cazzaniga fullname: Cazzaniga, Federico Angelo organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta – sequence: 11 givenname: Giovanni surname: Felisati fullname: Felisati, Giovanni organization: Department of Health Science, Santi Paolo e Carlo Hospital and Università degli Studi di Milano – sequence: 12 givenname: Giuseppe surname: Legname fullname: Legname, Giuseppe organization: Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA) – sequence: 13 givenname: Alessio surname: Di Fonzo fullname: Di Fonzo, Alessio organization: Unit of Neurology, Foundation IRCCS Ca’ Granda Ospedale Maggiore – sequence: 14 givenname: Rong surname: Xu fullname: Xu, Rong organization: Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine – sequence: 15 givenname: Steven Alexander surname: Gunzler fullname: Gunzler, Steven Alexander organization: Department of Neurology, Case Western Reserve University School of Medicine, Department of Neurology, University Hospitals Cleveland Medical Center – sequence: 16 givenname: Giorgio surname: Giaccone fullname: Giaccone, Giorgio organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta – sequence: 17 givenname: Roberto surname: Eleopra fullname: Eleopra, Roberto organization: Unit of Neurology 1 - Parkinson and Movement Disorders, Fondazione IRCCS Istituto Neurologico Carlo Besta – sequence: 18 givenname: Shu Guang surname: Chen fullname: Chen, Shu Guang email: sxc59@case.edu organization: Department of Pathology, Case Western Reserve University School of Medicine, Department of Neurology, Case Western Reserve University School of Medicine – sequence: 19 givenname: Fabio orcidid: 0000-0002-2820-9880 surname: Moda fullname: Moda, Fabio email: fabio.moda@istituto-besta.it organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34895275$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kstu1DAUhiNURC_wAiyQJTZsUnxJ7IQF0mi4jVTErayt40umHiXx1E6owrvwrnhmStupUOVFnJPv_51z_B9nB73vbZY9J_iUkIq_joRhWuSYkhzjoib59Cg7IqLEOWGUH9zZH2bHMa4SJDAun2SHrKjqkoryKPvzzkUdXOd6GJzvkW_Q5x-z_CuC3mx3c6Qm9P08_zYu5qkI7RRd3GC-bUAPPkyoG7WP8AYNFxY1LsQBQYw2xs72w4ZMbzChYNfBm1E75Vo3TEjZ4craHg1XHsW11Q5a99sa1ILyAZKxs_Fp9riBNtpn18-T7OeH9-fzT_nZl4-L-ews11ywIRcUY14rBQZMI5QxpKqbmhPMVI0ZYEErBaXBnBWlZUbUaZWAK04UNLQu2Em22PkaDyu5TvOAMEkPTm4LPiwlhMHp1kpSEFsUjSFc6AJKCg0IrgTTQK0pAZLX253XelSdNToNIUC7Z7r_pXcXcul_yYrzklGRDF5dGwR_Odo4yC7dkW1b6K0fo6Qc1wXnoqoT-vIeuvJjSJe0oQhhJa8wvaWWkBpwfePTuXpjKme8ZiXjKUiJOv0PlZaxndMpeY1L9T3Bi7uN3nT4L1wJoDtABx9jsM0NQrDcJFjuEixTguU2wXJKouqeSLthm830O659WMp20pjO6Zc23E7jAdVf4ccGQQ |
CitedBy_id | crossref_primary_10_1016_j_parkreldis_2025_107772 crossref_primary_10_3233_JPD_240007 crossref_primary_10_1212_WNL_0000000000200878 crossref_primary_10_1002_alz_13859 crossref_primary_10_1109_JSEN_2023_3272659 crossref_primary_10_3390_ijms251910783 crossref_primary_10_1007_s12311_022_01471_8 crossref_primary_10_1093_jnen_nlac042 crossref_primary_10_3389_fnagi_2022_872629 crossref_primary_10_1080_14737159_2024_2403073 crossref_primary_10_1002_mds_29828 crossref_primary_10_1038_s41572_022_00382_6 crossref_primary_10_3389_fnagi_2022_1010064 crossref_primary_10_1002_mdc3_13710 crossref_primary_10_1016_j_mcpro_2023_100629 crossref_primary_10_1186_s40478_024_01873_1 crossref_primary_10_1001_jamaneurol_2024_3458 crossref_primary_10_1016_j_neubiorev_2024_105997 crossref_primary_10_1371_journal_ppat_1012554 crossref_primary_10_3390_biom13081263 crossref_primary_10_1038_s41531_024_00728_9 crossref_primary_10_1186_s40035_023_00345_1 crossref_primary_10_3390_brainsci12111579 crossref_primary_10_1007_s00018_022_04240_2 crossref_primary_10_1186_s40035_025_00469_6 crossref_primary_10_3390_cells11010087 crossref_primary_10_3389_fnmol_2022_975619 crossref_primary_10_1016_j_parkreldis_2022_10_007 crossref_primary_10_1016_j_exger_2024_112366 crossref_primary_10_1111_ene_16041 crossref_primary_10_3389_fneur_2023_1210220 crossref_primary_10_1038_s41591_023_02358_9 crossref_primary_10_1016_j_tibtech_2024_01_007 crossref_primary_10_1186_s40035_023_00370_0 crossref_primary_10_1007_s11010_024_05190_y crossref_primary_10_1186_s40035_024_00449_2 crossref_primary_10_1186_s13578_023_01049_9 crossref_primary_10_1212_WNL_0000000000206881 crossref_primary_10_1038_s41531_023_00519_8 crossref_primary_10_1038_s41583_023_00697_7 |
Cites_doi | 10.1016/S1474-4422(20)30269-6 10.1016/j.autneu.2017.11.002 10.1001/jamaneurol.2016.4547 10.1007/s00401-020-02160-8 10.1016/j.autneu.2017.10.007 10.1002/mds.23972 10.1002/mds.27646 10.1212/01.wnl.0000324625.00404.15 10.1073/pnas.1909322116 10.1186/s40035-019-0164-x 10.1038/s41598-020-65324-2 10.1111/nan.12311 10.1038/nrneurol.2012.80 10.1002/mds.26424 10.1002/acn3.338 10.1093/brain/awf080 10.1002/ana.25447 10.1038/s12276-019-0350-z 10.1136/jnnp-2017-315813 10.1111/j.1365-2990.2007.00907.x 10.1016/j.isci.2020.101166 10.1111/j.1749-6632.2009.04365.x 10.1111/j.1365-2990.2007.00874.x 10.1038/s41586-020-2317-6 10.1093/brain/awz189 10.1016/S1474-4422(12)70327-7 10.1186/s40478-018-0508-2 10.1074/jbc.RA118.004471 10.1002/mds.28242 10.1002/acn3.50897 10.1038/s41586-020-1984-7 10.1093/braincomms/fcab045 10.1007/s11481-019-09835-4 10.1002/mds.22340 |
ContentType | Journal Article |
Copyright | The Author(s) 2021 2021. The Author(s). COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13024-021-00491-y |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central (New) ProQuest One Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 1750-1326 |
EndPage | 19 |
ExternalDocumentID | oai_doaj_org_article_141e44fd167c4a52afa76b73ca2ed5aa PMC8665327 A693536130 34895275 10_1186_s13024_021_00491_y |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | United States--US Italy |
GeographicLocations_xml | – name: United States--US – name: Italy |
GrantInformation_xml | – fundername: Michael J. Fox Foundation, Alzheimer’s Association, Alzheimer’s Research UK and the Weston brain Institute grantid: BAND 11035 – fundername: US National Institutes of Health (NIH)/National Institute on Aging grantid: R01AG061388 – fundername: Ministero della Salute grantid: GR-2013-02355724 and Current Research funderid: http://dx.doi.org/10.13039/501100003196 – fundername: Associazione Italiana Encefalopatie da Prioni (AIEnP) – fundername: American Parkinson Disease Association funderid: http://dx.doi.org/10.13039/100006309 – fundername: US National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke grantid: U01NS112010 and R01NS118760 – fundername: NINDS NIH HHS grantid: U01 NS112010 – fundername: NIA NIH HHS grantid: R01 AG061388 – fundername: NINDS NIH HHS grantid: R01 NS118760 – fundername: ; grantid: BAND 11035 – fundername: ; – fundername: ; grantid: U01NS112010 and R01NS118760 – fundername: ; grantid: GR-2013-02355724 and Current Research – fundername: ; grantid: R01AG061388 |
GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IHR INH INR IPY ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7TK 7XB 8FK AZQEC COVID DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c673t-720069bbadadf7bdd189f96103b903a0728ba5d06345e3d797975a0861baf2943 |
IEDL.DBID | M48 |
ISSN | 1750-1326 |
IngestDate | Wed Aug 27 01:06:35 EDT 2025 Thu Aug 21 18:20:22 EDT 2025 Fri Sep 05 04:47:14 EDT 2025 Fri Jul 25 03:32:07 EDT 2025 Tue Jun 17 21:30:36 EDT 2025 Tue Jun 10 20:29:40 EDT 2025 Mon Jul 21 05:59:54 EDT 2025 Tue Jul 01 01:59:05 EDT 2025 Thu Apr 24 23:08:35 EDT 2025 Sat Sep 06 07:29:29 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Real-Time Quaking-Induced Conversion Biomarkers Misfolding Alpha-synuclein Olfactory mucosa |
Language | English |
License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c673t-720069bbadadf7bdd189f96103b903a0728ba5d06345e3d797975a0861baf2943 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-2820-9880 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13024-021-00491-y |
PMID | 34895275 |
PQID | 2611356802 |
PQPubID | 55149 |
PageCount | 19 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_141e44fd167c4a52afa76b73ca2ed5aa pubmedcentral_primary_oai_pubmedcentral_nih_gov_8665327 proquest_miscellaneous_2609466789 proquest_journals_2611356802 gale_infotracmisc_A693536130 gale_infotracacademiconefile_A693536130 pubmed_primary_34895275 crossref_primary_10_1186_s13024_021_00491_y crossref_citationtrail_10_1186_s13024_021_00491_y springer_journals_10_1186_s13024_021_00491_y |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-12-11 |
PublicationDateYYYYMMDD | 2021-12-11 |
PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-11 day: 11 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Molecular neurodegeneration |
PublicationTitleAbbrev | Mol Neurodegeneration |
PublicationTitleAlternate | Mol Neurodegener |
PublicationYear | 2021 |
Publisher | BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
References | GM de Waal (491_CR24) 2020; 10 CH Hawkes (491_CR28) 2009; 1170 X Ding (491_CR29) 2020; 23 S Koga (491_CR4) 2018; 89 CG Goetz (491_CR22) 2008; 23 S Manne (491_CR17) 2020; 35 M Bongianni (491_CR34) 2019; 6 PG Glass (491_CR6) 2012; 27 RL Doty (491_CR5) 2012; 8 TR Yamasaki (491_CR10) 2019; 294 491_CR19 UJ Kang (491_CR20) 2019; 34 A van Rumund (491_CR33) 2019; 85 S Manne (491_CR14) 2019; 14 JQ Trojanowski (491_CR9) 2007; 33 BR Groveman (491_CR13) 2018; 6 CMG De Luca (491_CR16) 2019; 8 JA Palma (491_CR7) 2018; 211 M Shahnawaz (491_CR32) 2020; 578 S Gilman (491_CR1) 2008; 71 M Shahnawaz (491_CR15) 2017; 74 AJ Hughes (491_CR25) 2002; 125 CH Hawkes (491_CR27) 2007; 33 Z Wang (491_CR18) 2020; 78 H-J Lee (491_CR2) 2019; 51 E Valera (491_CR3) 2018; 211 Y Miki (491_CR11) 2019; 142 RB Postuma (491_CR21) 2015; 30 M Schweighauser (491_CR30) 2020; 585 GK Wenning (491_CR26) 2013; 12 M Rossi (491_CR31) 2020; 140 MG Spillantini (491_CR8) 2016; 42 A Pavel (491_CR35) 2020; 19 G Fairfoul (491_CR12) 2016; 3 MA Metrick (491_CR23) 2019; 116 |
References_xml | – volume: 19 start-page: 719 issue: 9 year: 2020 ident: 491_CR35 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(20)30269-6 – volume: 211 start-page: 1 year: 2018 ident: 491_CR3 publication-title: Auton Neurosci doi: 10.1016/j.autneu.2017.11.002 – volume: 74 start-page: 163 issue: 2 year: 2017 ident: 491_CR15 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2016.4547 – volume: 140 start-page: 49 issue: 1 year: 2020 ident: 491_CR31 publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02160-8 – volume: 211 start-page: 15 year: 2018 ident: 491_CR7 publication-title: Auton Neurosci doi: 10.1016/j.autneu.2017.10.007 – volume: 27 start-page: 327 issue: 2 year: 2012 ident: 491_CR6 publication-title: Mov Disord doi: 10.1002/mds.23972 – volume: 34 start-page: 536 issue: 4 year: 2019 ident: 491_CR20 publication-title: Mov Disord doi: 10.1002/mds.27646 – volume: 71 start-page: 670 issue: 9 year: 2008 ident: 491_CR1 publication-title: Neurology. doi: 10.1212/01.wnl.0000324625.00404.15 – volume: 116 start-page: 23029 issue: 46 year: 2019 ident: 491_CR23 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1909322116 – volume: 8 start-page: 24 issue: 1 year: 2019 ident: 491_CR16 publication-title: Transl Neurodegener doi: 10.1186/s40035-019-0164-x – volume: 10 start-page: 8777 issue: 1 year: 2020 ident: 491_CR24 publication-title: Sci Rep doi: 10.1038/s41598-020-65324-2 – volume: 42 start-page: 3 issue: 1 year: 2016 ident: 491_CR8 publication-title: Neuropathol Appl Neurobiol doi: 10.1111/nan.12311 – volume: 8 start-page: 329 issue: 6 year: 2012 ident: 491_CR5 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2012.80 – volume: 30 start-page: 1591 issue: 12 year: 2015 ident: 491_CR21 publication-title: Mov Disord doi: 10.1002/mds.26424 – volume: 3 start-page: 812 issue: 10 year: 2016 ident: 491_CR12 publication-title: Ann Clin Transl Neurol doi: 10.1002/acn3.338 – volume: 125 start-page: 861 issue: Pt 4 year: 2002 ident: 491_CR25 publication-title: Brain. doi: 10.1093/brain/awf080 – volume: 85 start-page: 777 issue: 5 year: 2019 ident: 491_CR33 publication-title: Ann Neurol doi: 10.1002/ana.25447 – volume: 51 start-page: 1 issue: 11 year: 2019 ident: 491_CR2 publication-title: Exp Mol Med doi: 10.1038/s12276-019-0350-z – volume: 89 start-page: 175 issue: 2 year: 2018 ident: 491_CR4 publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2017-315813 – volume: 33 start-page: 615 issue: 6 year: 2007 ident: 491_CR9 publication-title: Neuropathol Appl Neurobiol doi: 10.1111/j.1365-2990.2007.00907.x – volume: 23 start-page: 101166 issue: 6 year: 2020 ident: 491_CR29 publication-title: iScience doi: 10.1016/j.isci.2020.101166 – volume: 1170 start-page: 615 issue: 1 year: 2009 ident: 491_CR28 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2009.04365.x – volume: 33 start-page: 599 issue: 6 year: 2007 ident: 491_CR27 publication-title: Neuropathol Appl Neurobiol doi: 10.1111/j.1365-2990.2007.00874.x – volume: 585 start-page: 464 issue: 7825 year: 2020 ident: 491_CR30 publication-title: Nature. doi: 10.1038/s41586-020-2317-6 – volume: 142 start-page: 2813 issue: 9 year: 2019 ident: 491_CR11 publication-title: Brain. doi: 10.1093/brain/awz189 – volume: 78 start-page: 1 issue: 1 year: 2020 ident: 491_CR18 publication-title: JAMA Neurol – volume: 12 start-page: 264 issue: 3 year: 2013 ident: 491_CR26 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(12)70327-7 – volume: 6 start-page: 7 issue: 1 year: 2018 ident: 491_CR13 publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-018-0508-2 – volume: 294 start-page: 1045 issue: 3 year: 2019 ident: 491_CR10 publication-title: J Biol Chem doi: 10.1074/jbc.RA118.004471 – volume: 35 start-page: 2230 issue: 12 year: 2020 ident: 491_CR17 publication-title: Mov Disord doi: 10.1002/mds.28242 – volume: 6 start-page: 2120 issue: 10 year: 2019 ident: 491_CR34 publication-title: Ann Clin Transl Neurol doi: 10.1002/acn3.50897 – volume: 578 start-page: 273 issue: 7794 year: 2020 ident: 491_CR32 publication-title: Nature. doi: 10.1038/s41586-020-1984-7 – ident: 491_CR19 doi: 10.1093/braincomms/fcab045 – volume: 14 start-page: 423 issue: 3 year: 2019 ident: 491_CR14 publication-title: J NeuroImmune Pharmacol doi: 10.1007/s11481-019-09835-4 – volume: 23 start-page: 2129 issue: 15 year: 2008 ident: 491_CR22 publication-title: Mov Disord doi: 10.1002/mds.22340 |
SSID | ssj0047005 |
Score | 2.4821842 |
Snippet | Background
Detection of the pathological and disease-associated alpha-synuclein (αSyn
D
) in the brain is required to formulate the definitive diagnosis of... Detection of the pathological and disease-associated alpha-synuclein (αSyn ) in the brain is required to formulate the definitive diagnosis of multiple system... Background Detection of the pathological and disease-associated alpha-synuclein ([alpha]Syn.sup.D) in the brain is required to formulate the definitive... Detection of the pathological and disease-associated alpha-synuclein ([alpha]Syn.sup.D) in the brain is required to formulate the definitive diagnosis of... Background Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of... Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system... Abstract Background Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 82 |
SubjectTerms | Age Alpha-synuclein Alzheimer's disease Antibodies Atrophy Basal ganglia Biomarkers Biomedical and Life Sciences Biomedicine Central nervous system diseases Cerebellum Clinical trials COVID-19 Diagnosis Drug therapy Ethics Humans Laboratories Magnetic resonance imaging Misfolding Molecular Medicine Movement disorders Mucosa Multiple System Atrophy - pathology Neurodegenerative diseases Neurology Neuromuscular diseases Neurosciences Olfactory discrimination Olfactory discrimination learning Olfactory epithelium Olfactory mucosa Olfactory Mucosa - chemistry Olfactory Mucosa - pathology Parkinson Disease - diagnosis Parkinson Disease - pathology Parkinson's disease Patients Phenotypes Real-Time Quaking-Induced Conversion Reproducibility Reproducibility of Results Research Article Seeding Synuclein Tomography |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQUB6BgoyE4ABW49iObW7LQlWQini0Um-WndhipTZB7K5Q-C_8Vzx2dmmKgAvaSzaeSLbn83jGmXyD0GPGfHQKykAaXTrCndREWR5DFdo0wjWybCycQx69qw9P-NtTcXqh1BfkhGV64Dxx-5RTz3loaS0bbkVlg5W1k6yxlW-FTa5RqctNMJVtMJcRXJtPZFS9v4TXc5xAOgK4xJQMk20osfX_bpMvbEqXEyYvvTVNm9HBdXRt9CLxLPf-Brriu5tod9bFCPp8wE9wyutMB-a76MerBZgGSHkBJeA-4KNPM_Ie265NV3PsBvzxmHxYv5nHm5mkBMT6s1yNZ8DnkNduX-DoLeKwiA4jtltGT5CM_-yAgSAT-GNzwu2AxxwwvPrW42Wuc7_47ls8Aq-HKP0WOjl4fTw_JGNRBtLUkq2IhDMI7ZxtbRuka1uqdNDRCWNOl8yWslLOijZ6Plx41kodf8LGwIk6GyrN2W200_Wdv4swOHu-8papCA_nrbalUIFTx0LwoVUFohsdmWZkLIfCGWcmRS6qNlmvJurVJL2aoUDPts98yXwdf5V-CarfSgLXdroREWhGBJp_IbBATwE4BixC7F5jxw8b4iCBW8vMas0EgzitQHsTybiSm2nzBnpmtCRLEyNcykStyqpAj7bN8CRkx3W-X4NMCWUCpNIFupORuh0S40qLSooCyQmGJ2OetnSLz4lnHKgQWSUL9HyD9l_d-vOc3vsfc3ofXa1gtdKKULqHdlZf1_5B9P5W7mFa6D8BkQ1YWQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXLggoDwCBRkJwQGsxrEdx1zQslAVpCIerbS3yE9YqU1Kd1co_Bf-K568Soqo9rIbT6R4Zzz-Zjz5BqGnjPkICtJArEoN4UYqUmgeQxVqrTBWplZDHvLgY75_xD8sxKJPuK36ssrBJ7aO2tUWcuS7EelTJvIizV6f_iDQNQpOV_sWGlfRNRqRCLRukIsx4OIymtjwokyR767gkI4TKEoAYExJM9mMWs7-fz3zX1vTxbLJC2en7Za0dxPd6LEknnXKv4Wu-Oo22p5VMY4-afAz3FZ3tmnzbfT77RIcBBS-gCpwHfDB1xn5hHXl2m9zbBr85ZB83ryfx4sdVQmI1cddT54Gn0B1u36FI2bEYRlhI9YjrydIxl-6wUCTCSyyXdltg_tKMLz-WeNV1-1--cs73JtfDbH6HXS09-5wvk_61gzE5pKtiYRMhDJGO-2CNM7RQgUVoRgzKmU6lVlhtHAR_3DhmZMqfoSO4RM1OmSKs7toq6orfx9hgHw-85oV0UiM10qnogicGhaCD65IEB10VNqetxzaZxyXbfxS5GWn1zLqtWz1WjYJejHec9qxdlwq_QZUP0oC43Z7oT77VvYLOIZI1HMeHM2l5VpkOmiZG8mszrwTWifoORhOCX4hPp7V_esNcZLAsFXOcsUEg2gtQTsTybie7XR4ML2y9yer8tz6E_RkHIY7oUau8vUGZFJoFiALlaB7naWOU2K8UCKTIkFyYsOTOU9HquX3lm0cCBFZJhP0crD288f6_3_64PJZPETXM1iHNCOU7qCt9dnGP4robm0et0v4D5BrTq0 priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagXLggoDwCBRkJwQEs4tiObW7LQlWQini0Um-Wn-pKbYLorlD4L_xXPEl2acpDQnvJ2mMpzny2Z-zxNwg9Zixmo6BMxOvSEe6kJsry7KpQ74XzsvQW9iH339d7h_zdkTgaaXLgLsz583uq6hdncLDGCQQSgDFLSXcZXRG5ENA8r-frWZfLDKf1pZg_tpssPD0__--z8Lll6GKI5IVz0n752b2Oro12I54Nir6BLsXmJtqeNdlnPu3wE9xHcvZb5Nvox-sFTAYQ5AKfHbcJ73-ekQ_YNqF_mmPX4U8H5OPq7TwXDrQkINaeDPl3OnwKkez2Jc72IU6LbCJiu-HwBMn8z3YYKDGBMXYIse3wGPWFl99afDZktl98jwGPUGvBL7-FDnffHMz3yJiGgfhasiWRsOugnbPBhiRdCFTppLPZxZwumS1lpZwVIds6XEQWpM4_YbOrRJ1NlebsNtpq2ibeRRjMu1hFy1QGhItW21KoxKljKcUUVIHoWkfGjxzlkCrjxPS-iqrNoFeT9Wp6vZquQM82bb4MDB3_lH4Fqt9IArt2X5BBZ8bBmt0hGjlPgdbScysqm6ysnWTeVjEIawv0FIBjYA7Ir-fteJUhdxLYtMys1kww8MwKtDORzGPXT6vX0DPj3HFmsk9LmahVWRXo0aYaWkI8XBPbFciUkBhAKl2gOwNSN11iXGlRSVEgOcHwpM_TmmZx3DOLA_khq2SBnq_R_uu1_v5N7_2f-H10tYJxSStC6Q7aWn5dxQfZslu6h_2Q_gknakgI priority: 102 providerName: Springer Nature |
Title | Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories |
URI | https://link.springer.com/article/10.1186/s13024-021-00491-y https://www.ncbi.nlm.nih.gov/pubmed/34895275 https://www.proquest.com/docview/2611356802 https://www.proquest.com/docview/2609466789 https://pubmed.ncbi.nlm.nih.gov/PMC8665327 https://doaj.org/article/141e44fd167c4a52afa76b73ca2ed5aa |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELb6uHBBQHkEyspICA4QSGInTpAQSpdWZaVWpe1KvUV2YpeVtglsdwXhv_BfmXEekFIQyiGJPYnszEw8Y4-_IeQpYxqMAs-4eeIplyuRuLHk4Kr4eR6qXHi5xHnIg8Nof8onZ-HZGunSHbUf8PJa1w7zSU0X81ffvtTvQOHfWoWPo9eXuPjGXQw2QIPXd-t1smnXizCUj_erClx4NqQRRkzPBS8s6jbRXPuOwUBl8fz__Gv_NmxdDam8sq5qh6u9W-Rma2fStBGM22RNl3fIVlqCj31R02fURn7aKfUt8uP9DH8eGBSDbKKVoQcnqXtEZVnYqzFVNT0-dT-uPoyhsIExQbJq3uTrqekFRr7LNxTsSWpmYFJS2WN-IiXcyZoihCYizDYhuTVto8To8mtFcc8nKMPsuy5oK5oV-vF3yXRv93S877ZpG9w8EmzpCpylSJSShSyMUEXhx4lJwExjKvGY9EQQKxkWYBvxULNCJHCEElwrX0kTJJzdIxtlVeoHhKI5qAMtWQwCpLRMpBfGhvuKGaNNETvE73iU5S2mOabWmGfWt4mjrOFrBnzNLF-z2iEv-mc-N4ge_6TeQdb3lIjGbQuqxXnWKje4T77m3BR-JHIuw0AaKSIlWC4DXYRSOuQ5Ck6GUgzNy2W79QE6iehbWRolLGToyTlke0AJup4PqzvRyzpVycAH9lkYxV7gkCd9NT6J8XOlrlZI42EiAREnDrnfSGrfJcbjJAxE6BAxkOFBn4c15eyTRSJHsEQWCIe87KT9V7P-_k0f_kczH5EbASqjH7i-v002louVfgzm31KNyLo4EyOymaaTkwmcd3YPj46hdByNR3ZKZWS1_ifSF1vu |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZG9wAvCBiwwAAjcXkAa0nsxDHShLpuU8fWaoxO2lvwLVBpS8baagr_hb_Cb8Mnl44OsbepL218EsU9x-fm4-8g9IpS65wCPyNa-IowxQVJJHOhSqB1pDT3tYQ85GAY94_Yp-PoeAn9bs_CQFllqxMrRW0KDTnydefpBzSKEz_8ePaDQNco2F1tW2jIprWC2aggxpqDHXu2vHAh3GRjd8vx-3UY7myPen3SdBkgOuZ0SjgE1UIpaaTJuDImSEQmnFdBlfCp9HmYKBkZZ8pZZKnhwn0i6SKBQMksFIy6595CywwSKB20vLk9PDhsbQHjTsjbozpJvD6BbUJGoCwCXPOAlAvmsOoa8K9t-Ms4Xi3cvLJ7WxnFnXvobuPN4m4tfvfRks0foJVu7iL50xK_wVV9aZW4X0G_tsagoqD0BoQBFxkefOmSAyxzU33rYVXiwxH5PNvtuYs1WAqQFSd1V6ASn0J9vfyAndeKs7FzXLGcI4sCpfslSwxAnYBjWxf-lripRcPTiwLDyVK35MY_rcHNAiggW_AQHd0I2x6hTl7kdhVhcDptaCVNnJgqK4X0oyRjgaJZZjOTeChoeZTqBjkdGnicpFUElcRpzdfU8TWt-JqWHno3v-esxg25lnoTWD-nBMzv6kJx_i1tVIgL0gLLWGaCmGsmo1BmkseKUy1DayIpPfQWBCcFzeReT8vmgIWbJGB8pd1Y0IhCvOihtQVKp1H04nAremmj0Sbp5frz0Mv5MNwJVXq5LWZA40O7Ap4IDz2uJXU-JcoSEYU88hBfkOGFOS-O5OPvFd45QDLSkHvofSvtl6_1___0yfWzeIFu90eD_XR_d7j3FN0JYU0GIQmCNdSZns_sM-drTtXzZkFj9PWmdcgff3mROQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaglRAXBJRHoICREBwgahzbsc0tbFm1C60KbaXeLDuxYaU2qbq7QuG_8F_x5LF0y0NCuSTxWIozD8_Y428QekGpC05B4uNCJTZmVqhYGhZCFVIU3BYiKQysQ-7tZzvHbHLCTy6d4m-z3Yctye5MA6A0VfOt89J3Ki6zrRlst7EY0gvAxSVxcx2tS65UCL_W83xyOBmsMRNBzIbDMn_suTIhtbj9v1vnS9PT1dTJK_un7bQ0vo1u9f4kzjsBuIOuueou2sirEEufNfglbjM826XzDfRjewpGApJfgB249njvMI8PsKnK9m6EbYM_H8WfFruj8LKDKwGy-rSry9PgM8hwN29x8BuxnwbXEZsltidQhifTYIDKBCTZLvW2wX02GJ5_q_Gsq3g__e5K3ItgDfH6PXQ8fn802on78gxxkQk6jwWsRihrTWlKL2xZEqm8Cu4YtSqhJhGptIaXwQdi3NFSqHBxE0IoYo1PFaP30VpVV-4hwuD2udQZKoOgWGeUSbj0jFjqvfOljBAZeKSLHrscSmic6jaGkZnu-KoDX3XLV91E6PWyz3mH3PFP6nfA-iUloG63L-qLL7pX4hAmEceYL0kmCmZ4arwRmRW0MKkruTERegWCo8E2hM8rTH_EIQwSULZ0ninKKURsEdpcoQw6Xaw2D6Kne5sy0yHWJZRnMkkj9HzZDD0hT65y9QJoEigYIKSK0INOUpdDokwqngoeIbEiwytjXm2ppl9bxHEARaSpiNCbQdp_fdbf_-mj_yN_hm4cbI_1x939D4_RzRRUlKQxIZtobX6xcE-C8ze3T3v9_gkjjlS1 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discrimination+of+MSA-P+and+MSA-C+by+RT-QuIC+analysis+of+olfactory+mucosa%3A+the+first+assessment+of+assay+reproducibility+between+two+specialized+laboratories&rft.jtitle=Molecular+neurodegeneration&rft.au=Bargar%2C+Connor&rft.au=De+Luca%2C+Chiara+Maria+Giulia&rft.au=Devigili%2C+Grazia&rft.au=Elia%2C+Antonio+Emanuele&rft.date=2021-12-11&rft.issn=1750-1326&rft.eissn=1750-1326&rft.volume=16&rft.issue=1&rft.spage=82&rft_id=info:doi/10.1186%2Fs13024-021-00491-y&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1326&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1326&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1326&client=summon |